Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 1.00 |
| ▸ | ACE | P12821 | 3/20 | 1.00 |
| ▸ | MME | P08473 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.51 |
| ▸ | IL1RN | P18510 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidon SCHEMBL17813729 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL9100804 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL4436662 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL117398 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL14503212 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL8189183 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL7155564 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL8029985 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| Phosphoramidon SCHEMBL7300320 | 1.00 | ECE1 (1.00) | ECE1ACEMMELMNAERAP2 | |
| SCHEMBL20179087 | 0.87 | ECE1 (0.78) | ECE1ACEMMELMNAERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7601 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4427588-A2 | COMPOSITIONS FOR HEMOLYSIS AND COAGULATION REGULATION AND STABILIZATION OF EXTRACELLULAR VESICLES | Streck LLC (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | ACADIA WOODS PARTNERS, LLC | 2024-06-13 | — | — | US | claimed |
| EP-4308103-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | AI Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | claimed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | claimed |
| US-11759465-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| US-11693006-B2 | Blood profiling with protease inhibitors | SANGUI BIO PTY. LTD (AU) | 2023-07-04 | — | — | US | claimed |
| US-20230184786-A1 | Methods of Detecting and Treating Immune Responses Associated with Viral Infection | FORSYTH DENTAL INFIRMARY FOR CHILDREN, d/b/a THE FORSYTH INSTITUTE | 2023-06-15 | — | — | US | claimed |
| CN-114814013-B | Method for rapidly screening unknown chemical hazard residues in aquatic products based on high-resolution mass spectrum database | 中国海洋大学 | 2023-06-02 | — | — | CN | claimed |
| US-11612667-B2 | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors | ADVANCED ACCELERATOR APPLICATIONS USA INC (US) | 2023-03-28 | — | — | US | claimed |
| WO-1993005809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES OR NEUTRAL ENDOPEPTIDASE INHIBITORS FOR TREATING OR PREVENTING MYOINTIMAL PROLIFERATION | SCHERING CORPORATION (US) | 1993-04-01 | — | — | WO | claimed |
| EP-0533913-A1 | NOVEL ENDOPEPTIDASE | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 1993-03-31 | — | — | EP | claimed |
| EP-0533084-A1 | Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation | SCHERING CORPORATION (US) | 1993-03-24 | — | — | EP | claimed |
| WO-1992018159-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF NEPHROTOXICITY | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992018516-A1 | NOVEL ENDOPEPTIDASE | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0509442-A1 | Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity | SCHERING CORPORATION (US) | 1992-10-21 | — | — | EP | claimed |
| WO-1992013564-A1 | COMBINATION OF AN ANGIOTENSIN II ANTAGONIST OR RENIN INHIBITOR WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR | SCHERING CORPORATION (US) | 1992-08-20 | — | — | WO | claimed |
| WO-1992013944-A1 | ENDOTHELIN CONVERTING ENZYME | BERLEX LABORATORIES, INC. (US) | 1992-08-20 | — | — | WO | claimed |
| EP-0498361-A2 | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor | SCHERING CORPORATION (US) | 1992-08-12 | — | — | EP | claimed |
| EP-0348348-A2 | Process for controlling plant pests | CIBA-GEIGY AG (CH) | 1989-12-27 | — | — | EP | claimed |